Lion's Mane for memory and focus
Does Hericium erinaceus improve cognitive function in humans?
The idea
Lion's Mane is an edible mushroom — Hericium erinaceus, called yamabushitake in Japan — that contains two families of compounds, hericenones and erinacines, reported in laboratory work to stimulate nerve growth factor.
NGF supports the survival and growth of neurons. A food that promotes it is an appealing prospect, and it explains why Lion's Mane became the default entry point for anyone buying their first nootropic.
The human trials are small, few, and less consistent than the shelf presence suggests.
The trial everyone cites
Nearly every claim you will read traces to one study: a 2009 double-blind, placebo-controlled trial in Japanese adults aged 50–80 with mild cognitive impairment.1 Thirty participants were randomised into two groups of fifteen. The treatment group took 250 mg tablets, three times daily, for sixteen weeks.
At weeks 8, 12 and 16 the Lion's Mane group scored significantly higher on the cognitive scale than placebo, and scores rose with duration of intake. That is a real result and it is why this compound has the reputation it does.
Then there is the sentence that almost never gets quoted. After the sixteen weeks ended, participants were followed for four more weeks:
The Yamabushitake group's scores increased with the duration of intake, but at week 4 after the termination of the 16 weeks intake, the scores decreased significantly. Mori et al., Phytotherapy Research, 20091
This cuts both ways, and both matter. That the benefit tracked the intervention — appearing while taking it, fading after stopping — is evidence the effect was real rather than drift or placebo. It is also evidence the effect was symptomatic, not disease-modifying: nothing was durably changed. Stop taking it and you return to where you started.
Thirty people, one site, one team. This is a starting point that the field has never properly built on.
The trial nobody quotes properly
A 2023 pilot study gave 1.8 g daily to healthy adults aged 18–45 — 43 enrolled, 41 completing — testing both a single dose and 28 days of supplementation.2 It generated a wave of favourable coverage.
Here is its complete results ledger.
Read the ledger rather than the headline. The one clearly significant benefit was reaction speed on a single task. Meanwhile the memory findings ran against the supplement, and did so at stronger significance levels than the positive result — p=0.013 and p=0.002, versus p=0.005 for the Stroop and a stress finding at p=0.051 that does not reach significance at all.
The authors are candid about it, writing that "the negative effect is difficult to explain" and that the study was likely underpowered.2 That is the appropriate response to a confusing result in 41 people. It is not the impression left by coverage of it.
The rest of the literature
The Alzheimer's Drug Discovery Foundation's Cognitive Vitality programme — an independent nonprofit assessment, with no product to sell — identifies seven randomized controlled trials and summarises them bluntly.4
Thirty-one healthy adults over 50 across twelve weeks improved on one of three cognitive tests, with both groups improving over time. Forty-one healthy adults aged 18–45 recalled fewer words. Two further small trials in healthy young adults failed to improve cognition. In Alzheimer's patients over forty-nine weeks, activities of daily living improved but there were "no significant improvements in cognitive function."
A 2025 acute crossover trial in 18 healthy young adults adds to the pattern: no significant effect on global cognition or mood, improved manual dexterity on a pegboard task, and impaired performance on the Flanker and Trail Making B tests of executive function. Its authors called the results inconclusive.3
There is currently no evidence from large-scale randomized controlled trials that suggests that Lion's mane supplements are safe or beneficial for dementia patients. Cognitive Vitality, Alzheimer's Drug Discovery Foundation4
What "Lion's Mane" on a label doesn't tell you
This problem is more acute here than for any compound we have covered, and it deserves its own section.
Creatine is creatine. A mushroom extract is not a molecule — it is a preparation, and the amount of hericenones and erinacines it contains depends on which part of the organism was used, how it was grown, and how it was extracted. Fruiting body and mycelium are different material. Cognitive Vitality names the "lack of standardization in extraction methods and levels of bioactive compounds" as a limitation of the whole field.4
The practical consequence: even if a trial had found a robust benefit, you could not reliably reproduce its intervention by buying a product with the same name on the front. The trials cited here used specified preparations at specified doses. A capsule saying "Lion's Mane 1000 mg" does not tell you whether it contains what they used.
Why Emerging and Mixed
Two separate judgments, and the second is the more interesting one.
Emerging rather than Moderate because the verified participant total across the trials we could confirm sits well under 200 — thirty, forty-one, eighteen, thirty-one. These are pilot studies. Cognitive Vitality's own summary of the field is that trials "have included small numbers of participants with short durations of treatment."4
Mixed because the trials do not merely disagree about whether there is a benefit — some report the supplement performing worse than placebo on memory measures. A literature containing positive results, null results and negative results, none of them large, is the definition of an unresolved question.
Is there a variable that explains the split? A plausible one exists: benefit appears in older or cognitively impaired participants over long durations, while healthy young adults show null or negative results. That is a coherent story, and it may well be right.
It is also exactly the kind of pattern that small studies generate by chance. With thirty people in the positive trial and forty-one in the negative one, the population hypothesis has not been tested — it has been noticed. Under our conflict rule that leaves the verdict Mixed.
Two claims, two answers
The healthy-adult claim is the one most people are actually buying against, and it is the one where the trials most consistently fail — including two that found impairment on specific measures. The impaired-population claim rests on a single encouraging trial of thirty people that nobody has replicated at scale in seventeen years.
Safety and unknowns
-
Adverse events reported
Generally well tolerated. The 2009 trial reported no adverse effects on laboratory tests.1 Cognitive Vitality notes gastrointestinal discomfort, nausea, or skin rash in some people, and one case report of severe acute respiratory failure described as possibly related.4 A single case report establishes possibility, not incidence.
-
Longest human exposure studied
Forty-nine weeks, in the Alzheimer's trial.4 Most trials ran four to sixteen weeks. Nothing published characterises multi-year use.
-
Known interactions and at-risk groups
Not established by the sources reviewed here. As a mushroom product, allergy to fungi is the obvious caution; the trials cited do not address interactions with medication.
-
Regulatory status
Sold as a dietary supplement and as food. Not an approved treatment for any cognitive condition in any jurisdiction. No tolerable upper intake level established.
-
What has not been characterized
Effects beyond about a year. Whether the memory decrements seen in two trials are real or artefacts of small samples — this is the open question that matters most and nobody has powered a study to answer it. Product-level content of hericenones and erinacines, which is unstandardised across the market and unreported by most labels.
How this was graded
Evidence strength — Emerging, criteria checked
Participant counts are summed only across trials whose enrolment we could verify from the source. Cognitive Vitality identifies seven trials; we confirmed sizes for four. Grading on verified figures rather than estimates is why this sits at Emerging, and if the remaining trials push the total past 200 with the conflict unresolved, the grade would move to Moderate while the verdict stayed Mixed.
Bottom line
One encouraging trial in thirty people with mild cognitive impairment, seventeen years ago, has never been replicated at scale — and even in that trial the benefit disappeared within four weeks of stopping.
In healthy adults, the group most likely to be buying it, the trials are small and go in different directions. Two of them found participants on Lion's Mane doing worse than placebo on memory measures, at significance levels stronger than the benefits reported alongside. Those findings may be noise. Nobody has run a study large enough to say.
And because a mushroom extract is a preparation rather than a molecule, the product on the shelf may not contain what any trial tested. This is a reasonable thing to be curious about and a poor thing to be confident about.
Sources
- Mori K, Inatomi S, Ouchi K, Azumi Y, Tuchida T. Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment: a double-blind placebo-controlled clinical trial. Phytotherapy Research. 2009;23(3):367–372. PMID 18844328
- Docherty S, Doughty FL, Smith EF. The acute and chronic effects of lion's mane mushroom supplementation on cognitive function, stress and mood in young adults: a double-blind, parallel groups, pilot study. Nutrients. 2023;15(22):4842. PMC10675414
- Surendran G, Saye J, Binti Mohd Jalil S, et al. Acute effects of a standardised extract of Hericium erinaceus (Lion's Mane mushroom) on cognition and mood in healthy younger adults: a double-blind randomised placebo-controlled study. Frontiers in Nutrition. 2025;12:1405796. PMC12018234
- Alzheimer's Drug Discovery Foundation, Cognitive Vitality. Lion's Mane. alzdiscovery.org — independent nonprofit assessment, cited for its survey of the trial literature and safety observations.
